Reduced bendamustine for elderly patients with follicular lymphoma

Ann Hematol. 2022 Mar;101(3):713-715. doi: 10.1007/s00277-021-04576-y. Epub 2021 Jun 21.

Authors

Yosuke Masamoto¹, Arika Shimura¹, Mineo Kurokawa^{2

3}

Affiliations

¹ Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
² Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. [email protected].
³ Department of Cell Therapy and Transplantation Medicine, The University of Tokyo Hospital, Tokyo, Japan. [email protected].

No abstract available

Publication types

Letter

MeSH terms

Adult
Age Factors
Aged
Aged, 80 and over
Antineoplastic Agents, Alkylating / administration & dosage
Antineoplastic Agents, Alkylating / therapeutic use*
Bendamustine Hydrochloride / administration & dosage
Bendamustine Hydrochloride / therapeutic use*
Dose-Response Relationship, Drug
Female
Humans
Lymphoma, Follicular / drug therapy*
Lymphoma, Follicular / epidemiology
Male
Middle Aged
Retrospective Studies

Substances

Antineoplastic Agents, Alkylating
Bendamustine Hydrochloride